IMMUNOVIA
Immunovia is a strategic center for translational cancer research in Lund, Sweden. Immunovia’s strategy is to decipher a large amount of information in the blood and translate it into clinically useful tools to diagnose complex diseases such as cancer and to do this earlier and more accurately than previously possible. Immunovia’s core technology platform, IMMray™, is based on antibody microarray analysis.
IMMUNOVIA
Industry:
Biotechnology Clinical Trials Health Diagnostics
Founded:
2007-01-01
Address:
Lund, Skane Lan, Sweden
Country:
Sweden
Website Url:
http://www.immunovia.com
Total Employee:
11+
Status:
Active
Contact:
+46-46-275 60 00
Total Funding:
48.71 M USD
Technology used in webpage:
Viewport Meta IPhone / Mobile Compatible SPF SSL By Default LetsEncrypt Apple Mobile Web Clips Icon Google Tag Manager WordPress Apache Wordpress Plugins
Similar Organizations
Affimed
Affimed Therapeutics is focused on developing recombinant antibody therapeutics for the treatment of cancer and other diseases.
Current Advisors List
Board_member
2010-01-01
Current Employees Featured
Patrik Dahlen Chief Executive Officer @ Immunovia
Chief Executive Officer
2020-11-01
Philipp Mathieu CEO & President @ Immunovia
CEO & President
2022-06-01
Karin Almqvist Liwendahl CFO @ Immunovia
CFO
2021-10-01
Rolf Ehrnström Chief Scientific Officer @ Immunovia
Chief Scientific Officer
2013-03-01
Jeff Borcherding CEO of its US subsidiary @ Immunovia
CEO of its US subsidiary
2022-01-01
Founder
Stock Details
Investors List
EASME - EU Executive Agency for SMEs
EASME - EU Executive Agency for SMEs investment in Grant - Immunovia
Key Employee Changes
Official Site Inspections
http://www.immunovia.com Semrush global rank: 2.1 M Semrush visits lastest month: 9.83 K
- Host name: rackfish-websrv01.ad.rackfish.net
- IP address: 194.169.225.96
- Location: Sweden
- Latitude: 59.3247
- Longitude: 18.056
- Timezone: Europe/Stockholm
Immunovia.com lookup results from whois.namesrs.com server:
- Domain created: 17th-Jun-2007
- Domain updated: 14th-Feb-2025
- Domain expires: 17th-Jun-2025 0 Years, 79 Days left
- Website age: 17 Years, 286 Days
- Registrar Domain ID: 1033844703_DOMAIN_COM-VRSN
- Registrar Url: http://www.namesrs.com
- Registrar WHOIS Server: whois.namesrs.com
- Registrar Abuse Contact Email: abuse@namesrs.com
- Registrar Abuse Contact Phone: +46.313011220
- Name server:
- NS1.ILAIT.SE
- NS2.ILAIT.SE
- NS3.ILAIT.SE
- NS4.ILAIT.SE
More informations about "Immunovia"
Welcome to Immunovia Investor relations and stock …
Feb 25, 2025 Investor information including financial reports, the share, press releases, events, presentations and governanceSee details»
Immunovia, Inc. - LinkedIn
The World Health Organization was founded in 1948 with a mission to promote health, keep the world safe, and serve the vulnerable – so everyone, everywhere can attain the highest level of …See details»
Governance - Immunovia - Investor relations
Governance Immunovia AB (publ) is a Swedish public limited liability company, org. No. 556730-4299, with its registered office in Lund, Sweden. Immunovia has been a listed company since 2015, with shares traded (as IMMNOV) on …See details»
Immunovia - Crunchbase Company Profile & Funding
Immunovia is a diagnostics company that focuses on the early detection of pancreatic cancer through blood-based testing.See details»
Immunovia strengthens US organization to continue …
Dec 5, 2022 Immunovia is a diagnostic company with the vision to revolutionize blood-based diagnostics and increase survival rates for patients with cancer. Our first product, IMMray™ …See details»
Immunovia AB - LinkedIn
Immunovia AB is a diagnostic company that is developing and commercializing highly accurate blood tests for the early detection of cancer and autoimmune diseases based on Immunovia’s proprietary ...See details»
Immunovia initiates search for a new CFO to support …
Feb 21, 2025 Immunovia AB is a diagnostic company whose mission is to increase survival rates for patients with pancreatic cancer through early detection. Immunovia is focused on the …See details»
Headline presentation - Immunovia
Forward Looking Statements IMPORTANT: The following applies to this document, the oral presentation of the information in this document by Immunovia AB (publ) (the “Company”) or …See details»
Immunovia - Funding, Financials, Valuation & Investors
Immunovia is a diagnostics company that focuses on the early detection of pancreatic cancer through blood-based testing.See details»
Immunovia - Crunchbase Company Profile & Funding
Immunovia AB is a diagnostic company with the vision to revolutionize blood-based diagnostics and increase survival rates for patients with cancer.See details»
Immunovia to host a webcast to share more data from the …
Mar 21, 2025 Immunovia AB is a diagnostic company whose mission is to increase survival rates for patients with pancreatic cancer through early detection. Immunovia is focused on the …See details»
Immunovia has successfully acquired all blood samples required to ...
Oct 7, 2024 Immunovia AB is a diagnostic company whose mission is to increase survival rates for patients with pancreatic cancer through early detection. Immunovia is focused on the …See details»
Investment Case Immunovia: Promising clinical data and incoming ...
Dec 11, 2024 Read the full Investment Case by clicking the link below: Investment Case Immunovia (PDF) Immunovia was incorporated in 2007 and became a publicly traded …See details»
Immunovia launches a strategic partnership with Proteomedix to …
Oct 17, 2022 With this partnership, Immunovia will gain a more flexible R&D organization, increase its R&D productivity, and will focus internal resources on the commercial build up, …See details»
Press releases Archives - Immunovia
Feb 25, 2025 Immunovia’s CLARITI study results selected for prestigious presentation at the world’s largest gastroenterology conference Read press releaseSee details»
Immunovia initiates search for a new CFO to support …
Feb 21, 2025 Immunovia collaborates and engages with healthcare providers, leading experts and patient advocacy groups to make its test available to individuals at increased risk for …See details»
With New Clinical Data Readout, Immunovia Prepares for …
3 days ago NEW YORK – After announcing new clinical data last week on the performance of its next-generation pancreatic cancer test PancreaSure, Swedish diagnostic firm Immunovia is …See details»
Immunovia launches a strategic partnership with Proteomedix to …
Oct 17, 2022 With this partnership, Immunovia will gain a more flexible R&D organization, increase its R&D productivity, and will focus internal resources on the commercial build up, …See details»
Immunovia announces positive outcome and strong accuracy in …
Dec 9, 2024 In parallel, Immunovia will also conduct additional clinical studies to assess the test's accuracy, clinical impact and economic value across different high-risk patient groups.See details»
Immunovia publishes the annual report for 2022 - Immunovia
Apr 21, 2023 Immunovia is a diagnostic company with the vision to revolutionize blood-based diagnostics and increase survival rates for patients with cancer. Our first product, IMMray™ …See details»